Mr. Yuan Jiandong: Born in January 1970, Chinese nationality, with permanent residence in the United States, doctoral degree, chairman and general manager of the company. In June 1992, he graduated from Peking University with a bachelor's degree in chemistry; in May 1998, he graduated from the State University of New York with a doctoral degree in chemistry and received a PhD degree. From May 1998 to April 2001, he served as a senior researcher at EnzoBiochem Inc. in the United States. Since October 2001, he has served as chairman and general manager of the company and director of the Pharmaceutical Research Institute. From 2008 to 2015, he served as the executive director of Guangtai Biotech. From 2010 to present, he serves as executive director and general manager of Xintai Pharmaceutical and director of Borui Taixing. From 2011 to present, he serves as the chairman of Chongqing Qiantai. From 2014 to present, he serves as a director of Suzhou Naxin New Energy Technology Co., Ltd. From 2015 to present, he serves as a director of Suzhou Xinhai Biotechnology Co., Ltd. Yuan Jiandong has been engaged in research on the synthesis of innovative drugs and high-end generic drugs, and has led the research and development of a number of the company's patented technologies. He is the "intermediate and synthesis method of entecavir" and "precursor of L-nucleoside" used in the company's production and operations. Drugs", "Synthesis methods of antiviral nucleoside analogues", "Separation methods and polymorphs of single stereoisomers of argatroban", "Intermediates of avimopan and their synthesis methods", " "Nucleotide analog prodrugs and preparations thereof", "Tenofovir solids", "Tenofovir crystals", "Aliskiren intermediates and their preparation methods", "Sitagliptin One of the inventors of several patented technologies such as "Intermediates and Preparation Methods" and "A Synthesis Method of Oxiracetam".